View ValuationConvatec Group 향후 성장Future 기준 점검 4/6Convatec Group (는) 각각 연간 20% 및 6.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 20.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 24.4% 로 예상됩니다.핵심 정보20.0%이익 성장률20.07%EPS 성장률Medical Equipment 이익 성장13.5%매출 성장률6.1%향후 자기자본이익률24.37%애널리스트 커버리지Good마지막 업데이트27 May 2026최근 향후 성장 업데이트공시 • Nov 13Convatec Group plc Maintains Revenue Guidance for the Year 2025ConvaTec Group PLC maintained revenue guidance for the year 2025. FY25 Group organic revenue growth excluding InnovaMatrix 6.0-6.5% (previously 5.5-7.0%). Medium-term targets: 5-7% organic revenue.공시 • Jul 31+ 1 more updateConvaTec Group PLC Provides Revenue Guidance for the Year 2025ConvaTec Group PLC provided revenue guidance for the year 2025. Group organic revenue growth excluding InnovaMatrix of 5.5%-7.0% (unchanged) driven by broadening product portfolio and focused commercial execution. InnovaMatrix® revenue of at least $75 million (unchanged).공시 • May 17ConvaTec Group PLC Provides Revenue Guidance for the Full Year 2024ConvaTec Group PLC provided revenue guidance for the full year 2024. Given the strong start so far this year, the company expects more balanced growth between first half and the second half of the year, and the company is on track to deliver its full year guidance of 5% to 7% organic revenue growth.공시 • Nov 14ConvaTec Group PLC Revises Earnings Guidance for the Year 2023ConvaTec Group PLC revised earnings guidance for the year 2023. For the year, the company now expect organic revenue growth for 2023 to be between 6.75% and 7.5% (previously 6.0%-7.5%).공시 • May 19ConvaTec Group PLC Provides Revenue Guidance for the Year 2023ConvaTec Group PLC provided revenue guidance for the year 2023. For the year, the company now expects organic revenue growth to be between 5.0% and 6.5% (previously 4.5%-6.0%).공시 • Nov 10ConvaTec Group plc Provides Revenue Guidance for the Full Year of 2022ConvaTec Group Plc provided revenue guidance for the full year of 2022. Following sustained good sales growth, guidance for 2022 organic revenue growth has been increased to 5.4% to 5.8% (previously 4.0% to 5.5%.).모든 업데이트 보기Recent updatesBoard Change • May 20Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Group Financial Controller, CFO & Director Fiona Ryder was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • May 06Convatec Showcases and Launches Advanced Wound Care Products and TechnologiesConvatec, a medical products and technology company focused on chronic condition management, took to the stage to showcase the breadth, depth and momentum behind its Advanced Wound Care innovation pipeline at the European Wound Management Association (EWMA) 2026 conference in Bremen, Germany, from 6–8 May 2026. Convatec’s Advanced Wound Care innovation is supported by compelling new data from randomised controlled trials (RCTs) and real-world studies, with 13 abstracts accepted for publication and presentation at EWMA evaluating outcomes in hard-to-heal wounds across foam, multimodal, nitric oxide-generating dressings, antimicrobial technology and Wound Hygiene. Convatec has launched or secured approvals for five new wound care products since 2022, including: ConvaFoam™: Best-in-class multi-layer foam dressing designed to be repositionable on application to avoid wasted dressing changes. ConvaFoam™ is the only foam dressing that combines three technologies – Aquacel® Hydrofiber®, superabsorber fibers and ConvaTac™ silicone – to deliver superior exudate management with skin friendly adhesion for longer lasting wear time. ConvaNiox™: A solution, shaping a new category in the management of hard-to-heal wounds by combining an advanced dressing technology with a powerful antimicrobial and antibiofilm agent, nitric oxide. ConvaNiox™’s multimodal technology, MultiFusion™, supports the healing of 60% more diabetic foot ulcers (DFUs), with 3x faster wound area reduction compared to standard-of-care dressings. Aquacel™ ConvaFiber™: Next-generation, soft, sterile and conformable primary dressing with advanced Hydrofiber® technology resulting in 45% more absorbency (vs Aquacel® Extra™), designed to manage a broad range of acute and chronic wounds. ConvaMatrix™: Recently approved innovative, single use wound matrix - a unique porcine placental-derived technology designed to support the body's natural healing response in DFUs and venous leg ulcers (VLUs). It combines the structural benefits of the placenta with the reproducibility and safety profile of a medical device. ConvaVAC™: First and only Negative Pressure Wound Therapy (NPWT) system partnered with Aquacel® Hydrofiber® technology utilising a bacterial sequestration and autolytic debridement wound contact layer to control the bioburden whilst delivering NPWT to promote wound healing. This year’s EWMA programme also marks 30 years of Hydrofiber® technology, Convatec’s proprietary wound care platform that underpins the next generation of wound care innovation to help manage the burden of wound care. Almost 1,500,000,000 Aquacel® dressings have been sold worldwide leveraging the technology over the last three decades. As part of the scientific programme at EWMA 2026, Convatec will host a series of symposia to explore emerging evidence from across its Advanced Wound Care portfolio and discuss what it means for real-world clinical practice, including: 6 May 2026 from 16:00 – 17:00: Introducing ConvaNiox™: multimodal, nitric oxide-generating dressing. The session, chaired by Professor José Luis Lázaro-Martínez, University of Madrid, will explore emerging laboratory and clinical evidence, highlighting ConvaNiox™’s multimodal approach to support healing in diabetic foot ulcers. 7 May 2026 from 16:16 – 17:15: A year of healing with ConvaFoam™: Advancing wound care with a next-generation foam dressing. The session will focus on the published clinical data exploring ConvaFoam™’s mode of action in pressure injury prevention, including insights on complex cases from guest speaker Dr Przemyslaw Lipinski, ARGO Medical Centre. Title Lead presenter Session information (CEST) Aquacel® Ag+ Extra™ Enhanced silver dressing versus dialkylcarbamoyl chloride-coated dressing in venous leg ulcers: a blinded re-assessment of randomized controlled trial findings Rebecca Rodger Wednesday 6 May 17:35 - 17:43 Room 4B Enhanced silver dressing improves slough and debridement in venous leg ulcers: post hoc analysis of a randomised controlled trial Rebecca Rodger Thursday 07 May 13:33 – 13:37 E-Poster Screen 4 ConvaNiox™ Assessing the speed of antimicrobial activity of a nitric oxide-generating dressing against antibiotic-resistant wound pathogens Tilly Coleborn Wednesday 6 May 12:17 - 12:21 E-Poster Screen 2 Assessing the sustained antimicrobial activity of a nitric oxide-generating dressing using antibiotic-resistant wound pathogens in a repeated inoculation model Tilly Coleborn Wednesday 6 May 12:21 - 12:25 E-Poster Screen 2 A multimodal dressing NO-generating: An Option for Both Acute and Chronic Wounds Dr. Francesca Pasquali Wednesday 6 May 12:29 - 12:33 CEST E-Poster Screen 2 Effectiveness of a nitric oxide-generating dressing in patients with diabetic foot ulcers: preliminary data from a case series study Dr. Marco Meloni Thursday 7 May 13:20 - 13:25 E-Poster Screen 3 To assess real-world characteristics and short-term outcomes of diabetic foot ulcers (DFUs) managed with a multi-modal nitric oxide-generating medical device using a structured clinical follow-up case report form Natalia Maella-Rius Thursday 7 May 13:30 - 13:35 E-Poster Screen 3 ConvaFoam™ Performance and user satisfaction with a superabsorbent dressing: results from an international survey Janet MacKenzie Thursday 7 May 12:54 – 12:57 E-Poster Screen 2 Early outcomes of implementing a new multilayer foam dressing in an acute setting: Assessing clinical and financial impact through value-based procurement Rebecca Rodger Thursday 7 May 16:10 - 16:15 E-Poster Screen 4 ConvaMatrix™ The clinical performance of decellularized porcine placental extracellular matrix (PPECM) in hard-to-heal wounds at a single-center: a retrospective study Helen Hahn Wednesday 6 May 00:00 - 00:00 E-poster browsing stations for display Real-world use of porcine placental extracellular matrix (PPECM) in hard-to-heal wounds: retrospective, multicenter analysis Helen Hahn Wednesday 6 May 00:00 - 00:00 E-poster browsing stations for display Real world data Hospital-to-home transition and care coordination in wound management: cost-effectiveness evaluation in a Brazilian specialized service Michele Rocha Thursday 7 May 10:36 - 10:39 E-Poster Screen 4 Therapeutic success indicators in hard-to-heal wounds: effectiveness of a specialized ambulatory care model Michele Rocha Thursday 7 May 16:30 - 16:35 E-Poster Screen 4.공시 • Apr 13Convatec Group Plc Announces Professor Constantin Coussios OBE Steps Down as Non-Executive Director, Effective April 30, 2026Convatec Group Plc announces that Professor Constantin Coussios OBE will be stepping down as a Non-Executive Director of Convatec Group Plc with effect from April 30, 2026 as he takes up his new appointment as Pro-Vice-Chancellor for Innovation at the University of Oxford. Since his appointment in September 2020, Professor Coussios has worked closely with the Board, senior management and Convatec's Chief Science, Innovation & Quality Officer Dr Divakar Ramakrishnan to transform and re-shape Convatec's research and development capabilities, accelerate new product development, and position the Company for sustained, innovation-led growth. Over the past six years, Convatec has completed several transformative strategic acquisitions, its internal new product development cycle time has been compressed by approximately 30%, and the vitality index has strengthened steadily from approximately 10% to approximately 30%, with 16 new product launches underway since 2022. The company confirms that the resolution to re-elect Professor Coussios as a Non-Executive Director of the company (resolution number 9) is now withdrawn.공시 • Mar 18Convatec Group PLC to Report First Half, 2026 Results on Aug 04, 2026Convatec Group PLC announced that they will report first half, 2026 results on Aug 04, 2026공시 • Mar 17Convatec and Eakin Healthcare Introduce Co-Branded Eakin Freeseal Ostomy Seal in North America Expanding the Esenta Family of AccessoriesConvatec, a medical products and technologies company focused on solutions for the management of chronic conditions, and Eakin Healthcare, a provider of ostomy solutions, announced the launch of eakin freeseal, the thinnest ostomy seal used to help prevent leaks and protect the skin around a stoma. This new co-branded seal is part of the ESENTA family of accessories, available in the United States. Ostomy seals are designed to create a protective layer around the stoma to prevent leakage. Recurrent leakage can lead to skin breakdown and irritation, leading to longer term issues, both physically and emotionally for patients. With approximately 1 million people living with a stoma in the United States, about 90% experience leakage at some point in their journey. The use of ostomy seals can reduce or eliminate leakage, leading to a better quality of life for those living with an ostomy. The eakin freeseal range includes two product lines, eakin freeseal air, and eakin freeseal versa, providing healthcare professionals with versatile options that combine discretion, comfort and high performance. While Convatec currently addresses the patient's needs with the eakin Cohesive seal, eakin freeseal provides healthcare professionals with a wider range of options to meet their clinical needs. The thinner offering, eakin freeseal air has a depth starting at 1.8mm, making it the thinnest seal on the market and is designed to be paired with convex pouches. Eakin freeseal versa is slightly thicker and designed to absorb fluid at the best rate in the market without breaking down, leading to easier removal for the end user. The thinness of this new ostomy seal, together with its composition and design, allows it to absorb up to four times its weight in fluid without breaking down underneath the skin barrier. This high performance, combined with eakin seals’ moldability, makes eakin freeseal a relatable solution to any person living with a stoma immediately post-surgery. Ostomy seals and barriers designed to prevent leakage and skin irritation is one of the largest product categories in the United States and continues to grow at a consistent rate. This co-branded product reflects Convatec and Eakin Healthcare’s ongoing commitment to patients and healthcare professionals to provide choice – working together to provide a better ostomy experience so patients can live the life they want. Integrating eakin seals into the ESENTA range reinforces the importance of using a reliable ostomy seal as part of the customers skincare routine.공시 • Feb 25Convatec Group PLC, Annual General Meeting, May 21, 2026Convatec Group PLC, Annual General Meeting, May 21, 2026.공시 • Feb 24Convatec Group PLC Recommends Final Dividend for the Year 2025, Payable on 28 May 2026Convatec Group PLC has recommended a final 2025 dividend of 5.367 cents per share, which would bring the full-year dividend to 7.244 cents per share (2024: 6.416 cents per share), an increase of 13% and a pay-out ratio when compared to adjusted net profit of 40% (2024: 42%). Ex-dividend is on 16 April 2026 with Record date on 17 April 2026. Payment date on 28 May 2026.공시 • Nov 13Convatec Group plc Maintains Revenue Guidance for the Year 2025ConvaTec Group PLC maintained revenue guidance for the year 2025. FY25 Group organic revenue growth excluding InnovaMatrix 6.0-6.5% (previously 5.5-7.0%). Medium-term targets: 5-7% organic revenue.공시 • Nov 08+ 2 more updatesConvaTec Group PLC Appoints Jonny Mason as Chief Executive Officer, Effective November 6, 2025ConvaTec Group PLC Board of Directors announced the appointment of Jonny Mason as Chief Executive Officer, effective November 6, 2025.Jonny Mason joined Convatec on 31 January 2022 as Chief Financial Officer and became a Director of the Company from 12 March 2022. He was appointed Interim CEO on 4 August 2025.공시 • Oct 28Convatec Group plc Announces Demise of Karim Bitar, Chief Executive OfficerConvaTec Group PLC announced that its Karim Bitar, who has been on medical leave of absence since 4 August 2025, has passed away. As previously announced, interim leadership arrangements remain in place and a further announcement will be made in due course.공시 • Aug 04+ 1 more updateConvaTec Group PLC Announces Change of Chief Executive OfficerConvatec announced that Chief Executive Officer Karim Bitar will be taking a medical leave of absence from the Company. During this period of absence, Jonny Mason, currently Chief Financial Officer, will become Interim Chief Executive Officer. Jonny and Fiona joined the Company in January 2022.공시 • Jul 31+ 1 more updateConvaTec Group PLC Provides Revenue Guidance for the Year 2025ConvaTec Group PLC provided revenue guidance for the year 2025. Group organic revenue growth excluding InnovaMatrix of 5.5%-7.0% (unchanged) driven by broadening product portfolio and focused commercial execution. InnovaMatrix® revenue of at least $75 million (unchanged).공시 • Jul 29ConvaTec Group PLC to Report Fiscal Year 2025 Results on Feb 25, 2026ConvaTec Group PLC announced that they will report fiscal year 2025 results on Feb 25, 2026공시 • Feb 27ConvaTec Group PLC, Annual General Meeting, May 22, 2025ConvaTec Group PLC, Annual General Meeting, May 22, 2025.공시 • Feb 26+ 1 more updateConvaTec Group PLC Recommends Final Dividend for the Year 2024, Payable on 29 May 2025The Board of ConvaTec Group PLC recommends a final dividend of 4.594 cents, resulting in a full year dividend of 6.416 cents, an increase of 3%. The final dividend proposed for 2024 is to be distributed on 29 May 2025 to shareholders on the register at the close of business on 22 April 2025 and is subject to shareholder approval at the Annual General Meeting on 22 May 2025. Ex-dividend 17 April 2025.공시 • Dec 17ConvaTec Group PLC to Report Fiscal Year 2024 Results on Feb 26, 2025ConvaTec Group PLC announced that they will report fiscal year 2024 results on Feb 26, 2025New Risk • Nov 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (75% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.1% average weekly change).Valuation Update With 7 Day Price Move • Nov 13Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €3.04, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €4.83 per share.Upcoming Dividend • Aug 16Upcoming dividend of UK£0.014 per shareEligible shareholders must have bought the stock before 22 August 2024. Payment date: 04 October 2024. Payout ratio is on the higher end at 84%, however this is supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (1.9%).Declared Dividend • Aug 02First half dividend of UK£0.014 announcedShareholders will receive a dividend of UK£0.014. Ex-date: 22nd August 2024 Payment date: 4th October 2024 Dividend yield will be 2.0%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (84% earnings payout ratio) and cash flows (50% cash payout ratio). The dividend has increased by an average of 12% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 76% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Aug 01First half 2024 earnings released: EPS: US$0.038 (vs US$0.027 in 1H 2023)First half 2024 results: EPS: US$0.038 (up from US$0.027 in 1H 2023). Revenue: US$1.11b (up 5.5% from 1H 2023). Net income: US$78.6m (up 41% from 1H 2023). Profit margin: 7.1% (up from 5.3% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 2% per year.공시 • May 17ConvaTec Group PLC Provides Revenue Guidance for the Full Year 2024ConvaTec Group PLC provided revenue guidance for the full year 2024. Given the strong start so far this year, the company expects more balanced growth between first half and the second half of the year, and the company is on track to deliver its full year guidance of 5% to 7% organic revenue growth.Upcoming Dividend • Apr 18Upcoming dividend of UK£0.035 per shareEligible shareholders must have bought the stock before 25 April 2024. Payment date: 23 May 2024. Payout ratio is on the higher end at 97%, however this is supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (1.8%).공시 • Apr 16Convatec Launches New Esteem Body with Leak DefenseConvatec announced that it has launched Esteem Body™ with Leak Defense™ in the United States. The use of soft convexity ostomy barriers, starting post-surgery, is a growing practice fueled in part by global obesity, which has nearly tripled since 1975. The trend has driven abdominal topography changes and related challenges for ostomy care management, such as skin folds and complicated abdominal contours. Convatec's new offering to address this growing patient need is a comprehensive, one-piece, soft convexity ostomy system portfolio designed to fit a full range of body types and stoma shapes. The portfolio includes drainable, closed-end, and urostomy pouching solutions. There are five principal characteristics of convexity design, with two of these – 'tension location' and 'convex depth' - serving as significant drivers for achieving clinical goals of stoma protrusion and/or skin flattening. Convatec's Esteem Body™ offers eight different combinations of these key characteristics, with four 'tension locations' (split centrally and peripherally) across two different 'convex depths'. This range gives greater choice and provides the healthcare provider and ostomate the ability to achieve the best possible fit, given that each person living with an ostomy is unique. Leak Defense™ refers to the exclusive combination of Convatec's gold-standard adhesives (Durahesive® and Modified Stomahesive®) coupled with the comprehensive, soft convexity range, which together are designed to adapt to the body for a secure seal that can help prevent leaks and achieve a predictable wear time. The product also offers Convatec's new 'body' pouch, which comes in a patented '8-shape' that has been designed to sag less as it fills. The soft yet water-repellent 'flocking' material, that covers both sides of the pouch, is a warm gray color that hides content, even when wet, and is also discreet, even when worn under white clothing. The flocking was selected to optimise the functionality and discretion of Convatec's new, modern-looking and feeling pouch design. Convatec has recently published Finite Element Analysis (FEA) simulations that help visualize how both magnitude and location, of the tension applied to the ostomy and its surrounding multi-layer tissue, change in accordance with the product selected. It was clear how both tension location and convex depth are key contributors, working together with all convexity characteristics to achieve clinical stoma management goals. The FEA work is the foundation for the scientific and translational work Convatec is doing in ostomy care, and upon which research will be expanded to support clinicians and ostomates.공시 • Mar 08+ 1 more updateConvaTec Group plc Recommends Final Dividend, Payable on 23 May 2024ConvaTec Group PLC recommended final dividend of 4.460 cents resulting in full year dividend of 6.229 cents, an increase of 3%. The dividend will be payable on 23 May 2024 with Ex Dividend of 25 April 2024 and Record Date of 26 April 2024. The dividend is subject to shareholder approval at the Annual General Meeting on 16 May 2024.Reported Earnings • Mar 07Full year 2023 earnings released: EPS: US$0.064 (vs US$0.031 in FY 2022)Full year 2023 results: EPS: US$0.064 (up from US$0.031 in FY 2022). Revenue: US$2.14b (up 3.4% from FY 2022). Net income: US$130.3m (up 107% from FY 2022). Profit margin: 6.1% (up from 3.0% in FY 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.공시 • Mar 06ConvaTec Group PLC, Annual General Meeting, May 16, 2024ConvaTec Group PLC, Annual General Meeting, May 16, 2024. Agenda: To consider Final Dividend.공시 • Feb 16ConvaTec Group PLC to Report First Half, 2024 Results on Jul 30, 2024ConvaTec Group PLC announced that they will report first half, 2024 results on Jul 30, 2024Buy Or Sell Opportunity • Feb 15Now 20% undervaluedOver the last 90 days, the stock has risen 7.7% to €2.80. The fair value is estimated to be €3.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has declined by 6.6%. For the next 3 years, revenue is forecast to grow by 5.3% per annum. Earnings are also forecast to grow by 24% per annum over the same time period.Buying Opportunity • Jan 05Now 21% undervaluedOver the last 90 days, the stock is up 10%. The fair value is estimated to be €3.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has declined by 6.6%. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings is also forecast to grow by 27% per annum over the same time period.공시 • Nov 14ConvaTec Group PLC Revises Earnings Guidance for the Year 2023ConvaTec Group PLC revised earnings guidance for the year 2023. For the year, the company now expect organic revenue growth for 2023 to be between 6.75% and 7.5% (previously 6.0%-7.5%).공시 • Sep 14ConvaTec Group PLC to Report Fiscal Year 2023 Results on Mar 06, 2024ConvaTec Group PLC announced that they will report fiscal year 2023 results on Mar 06, 2024공시 • Sep 08+ 1 more updateAn unknown buyer acquired an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S.An unknown buyer acquired an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S on September 8, 2023. Sten Scheibye will be stepping down from the Board. An unknown buyer completed the acquisition of an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S on September 8, 2023.Upcoming Dividend • Aug 10Upcoming dividend of UK£0.014 per share at 2.1% yieldEligible shareholders must have bought the stock before 17 August 2023. Payment date: 28 September 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.9%).공시 • Aug 04+ 1 more updateConvaTec Group plc Declares Interim Dividend for the Six Months Ended June 30, 2023ConvaTec Group PLC is declaring a 3% increase in the interim dividend to 1.769 cents per share (H1 2022: 1.717) reflecting continued confidence in the future performance of the Group and cash generation.New Risk • Aug 03New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 18% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Payout ratio: 176% Cash payout ratio: 111% Minor Risk Large one-off items impacting financial results.Reported Earnings • Aug 03First half 2023 earnings released: EPS: US$0.027 (vs US$0.024 in 1H 2022)First half 2023 results: EPS: US$0.027 (up from US$0.024 in 1H 2022). Revenue: US$1.06b (up 1.1% from 1H 2022). Net income: US$55.7m (up 15% from 1H 2022). Profit margin: 5.3% (up from 4.6% in 1H 2022). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Buying Opportunity • Jul 24Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €3.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 4.4% per annum. Earnings is also forecast to grow by 26% per annum over the same time period.Buying Opportunity • Jul 06Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 7.1%. The fair value is estimated to be €2.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 4.4% per annum. Earnings is also forecast to grow by 25% per annum over the same time period.공시 • May 19ConvaTec Group PLC Provides Revenue Guidance for the Year 2023ConvaTec Group PLC provided revenue guidance for the year 2023. For the year, the company now expects organic revenue growth to be between 5.0% and 6.5% (previously 4.5%-6.0%).Upcoming Dividend • Mar 30Upcoming dividend of UK£0.037 per share at 2.2% yieldEligible shareholders must have bought the stock before 06 April 2023. Payment date: 25 May 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.2%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).Reported Earnings • Mar 10Full year 2022 earnings released: EPS: US$0.031 (vs US$0.059 in FY 2021)Full year 2022 results: EPS: US$0.031 (down from US$0.059 in FY 2021). Revenue: US$2.07b (up 1.7% from FY 2021). Net income: US$62.9m (down 47% from FY 2021). Profit margin: 3.0% (down from 5.8% in FY 2021). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Dec 24Group CFO & Director recently bought €73k worth of stockOn the 19th of December, Jonathan Mason bought around 28k shares on-market at roughly €2.60 per share. This transaction increased Jonathan's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jonathan has been a buyer over the last 12 months, purchasing a net total of €131k worth in shares.공시 • Dec 14ConvaTec Group Plc to Report Fiscal Year 2022 Results on Mar 09, 2023ConvaTec Group Plc announced that they will report fiscal year 2022 results on Mar 09, 2023Board Change • Nov 17High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Group CFO & Director Jonny Mason was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Nov 10ConvaTec Group plc Provides Revenue Guidance for the Full Year of 2022ConvaTec Group Plc provided revenue guidance for the full year of 2022. Following sustained good sales growth, guidance for 2022 organic revenue growth has been increased to 5.4% to 5.8% (previously 4.0% to 5.5%.).Buying Opportunity • Nov 03Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €3.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 26% per annum over the same time period.공시 • Sep 19+ 1 more updateConvaTec Group Plc(LSE:CTEC) dropped from FTSE 250 IndexConvaTec Group Plc(LSE:CTEC) dropped from FTSE 250 IndexBuying Opportunity • Sep 03Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 4.7%. The fair value is estimated to be €3.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 3.6% per annum. Earnings is also forecast to grow by 31% per annum over the same time period.Upcoming Dividend • Aug 18Upcoming dividend of UK£0.014 per shareEligible shareholders must have bought the stock before 25 August 2022. Payment date: 06 October 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (1.1%).Reported Earnings • Aug 05First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down US$85.8m from profit in 1H 2021). Profit margin: (down from 8.5% in 1H 2021). Over the next year, revenue is forecast to grow 1.2%, compared to a 7.2% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 15% per year.공시 • Aug 04+ 1 more updateConvatec Group plc Declares an Unchanged Interim Dividend for First Half of 2022ConvaTec Group Plc announced that the Board is declaring an unchanged interim dividend of 1.717 cents per share (H1 2021: 1.717) reflecting continued confidence in the future performance of the Group and cash generation.공시 • May 12ConvaTec Group Plc Provides Earnings Guidance for the Full Year 2022ConvaTec Group Plc provides earnings guidance for the full year 2022. For the period, the company expects organic revenue growth of between 4.0% and 5.5% and a constant currency EBIT margin of at least 18%.Board Change • Apr 27High number of new directorsThere are 8 new directors who have joined the board in the last 3 years. Group CFO & Director Jonny Mason was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Mar 24Upcoming dividend of UK£0.032 per shareEligible shareholders must have bought the stock before 31 March 2022. Payment date: 19 May 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.2%. Lower than top quartile of German dividend payers (3.6%). Higher than average of industry peers (1.1%).공시 • Mar 10Convatec Group plc Proposes Final Dividend for Year 2021, Payable on May 19, 2022ConvaTec Group Plc proposed the final dividend of 4.154 cents for year 2021, to be distributed on 19 May 2022 to shareholders registered at the close of business on 1 April 2022, is based upon the issued and fully paid share capital as at 31 December 2021 and is subject to shareholder approval at the Annual General Meeting on 12 May 2022. Ex-dividend date is March 31, 2022.Reported Earnings • Mar 09Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$0.059 (up from US$0.056 in FY 2020). Revenue: US$2.04b (up 7.6% from FY 2020). Net income: US$117.6m (up 4.5% from FY 2020). Profit margin: 5.8% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 3.5%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.Reported Earnings • Mar 09Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$0.059 (up from US$0.056 in FY 2020). Revenue: US$2.04b (up 7.6% from FY 2020). Net income: US$117.6m (up 4.5% from FY 2020). Profit margin: 5.8% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 3.5%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.공시 • Mar 01Convatec Group plc Announces Board ChangesConvaTec Group Plc announced the appointment of Sharon O'Keefe as a Non-Executive Director of the Company with effect from March 1, 2022. Sharon will join ConvaTec's Remuneration and Nomination committees on the same date. The Company also announces that Rick Anderson, Non-Executive Director, is stepping down from the Board with effect from 3 March 2022. Rick has made a significant and valuable contribution to ConvaTec since 2016 for which the Board is immensely grateful. Rick is also Chairman and MD of Revival Healthcare Capital, a role which has recently expanded, and this has led to his reluctant decision to step down from the Board of ConvaTec. Sharon has over 40 years of healthcare and executive experience, with particular focus on quality, efficiency and innovation to create high performance healthcare organisations.공시 • Jan 30ConvaTec Group Plc (LSE:CTEC) agreed to acquire Triad Life Sciences, Inc. for $450 million.ConvaTec Group Plc (LSE:CTEC) agreed to acquire Triad Life Sciences, Inc. for $450 million on January 28, 2022. The initial consideration is $125 million with two potential additional payments of $25 million each relating to short-term milestones. There are also two earnout payments conditional on performance during year 1 and year 2 post completion, with the maximum earnout of $275 million based on stretching financial performance over the period. The consideration will be satisfied from existing cash balances and debt facilities. The gross assets of Triad Life Sciences were $23 million at 30 June 2021. Russell Olsen, the Founder and Chief Executive Officer of Triad Life Sciences, will be the General Manager of the business, reporting directly into David Shepherd, President and Chief Operating Officer of Global Advanced Wound Care. The transaction, which is subject to regulatory approvals and other customary conditions, is expected to close during Q1 2022. The transaction is expected to be immediately accretive to sales growth and the return on invested capital is expected to exceed the Group's cost of capital in year three.공시 • Jan 28ConvaTec Group Plc Appoints Constantin Coussios as Member of Remuneration Committee and Nomination CommitteeConvaTec Group Plc announced that Professor Constantin Coussios, a Non-Executive Director of the Company, has been appointed as a member of the Company's Remuneration Committee and Nomination Committee.Upcoming Dividend • Aug 26Upcoming dividend of UK£0.012 per shareEligible shareholders must have bought the stock before 02 September 2021. Payment date: 14 October 2021. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (3.1%). Higher than average of industry peers (0.8%).Reported Earnings • Aug 01First half 2021 earnings released: EPS US$0.043 (vs US$0.03 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$1.01b (up 11% from 1H 2020). Net income: US$85.8m (up 45% from 1H 2020). Profit margin: 8.5% (up from 6.5% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Executive Departure • May 04Company Secretary has left the companyOn the 30th of April, Clare Bates' tenure in the role of Company Secretary ended. We don't have any record of a personal shareholding under Clare's name. A total of 2 executives have left over the last 12 months.공시 • Apr 29ConvaTec Group plc Provides Financial Guidance for the Year 2021ConvaTec Group Plc provided financial guidance for the year 2021. Given the continuing macro uncertainties at this early point in the year and relatively tougher comparatives in the second half, guidance remains unchanged with organic1 revenue growth of 3% to 4.5%.Upcoming Dividend • Mar 26Upcoming dividend of UK£0.028 per shareEligible shareholders must have bought the stock before 01 April 2021. Payment date: 13 May 2021. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.3%). Higher than average of industry peers (1.1%).Reported Earnings • Mar 24Full year 2020 earnings released: EPS US$0.056 (vs US$0.005 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$1.89b (up 3.7% from FY 2019). Net income: US$112.5m (up US$102.7m from FY 2019). Profit margin: 5.9% (up from 0.5% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Reported Earnings • Mar 06Full year 2020 earnings released: EPS US$0.056 (vs US$0.005 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$1.89b (up 3.7% from FY 2019). Net income: US$112.5m (up US$102.7m from FY 2019). Profit margin: 5.9% (up from 0.5% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Analyst Estimate Surprise Post Earnings • Mar 06Revenue beats expectationsRevenue exceeded analyst estimates by 0.4%. Over the next year, revenue is forecast to grow 5.6%, compared to a 13% growth forecast for the Medical Equipment industry in Germany.공시 • Mar 05Convatec Group Plc, Annual General Meeting, May 07, 2021Convatec Group Plc, Annual General Meeting, May 07, 2021.공시 • Feb 23Convatec Group Plc to Report Fiscal Year 2020 Results on Mar 05, 2021Convatec Group Plc announced that they will report fiscal year 2020 results on Mar 05, 2021Is New 90 Day High Low • Feb 23New 90-day low: €2.16The company is down 4.0% from its price of €2.26 on 24 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.39 per share.Is New 90 Day High Low • Feb 04New 90-day high: €2.30The company is up 8.0% from its price of €2.13 on 06 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.40 per share.Is New 90 Day High Low • Nov 11New 90-day high: €2.25The company is up 3.0% from its price of €2.18 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.91 per share.공시 • Oct 29Convatec Group plc Revises Revenue Guidance for the Year 2020Convatec Group Plc revised full year guidance and now expect to be towards the higher end of constant currency revenue growth range of 2%-3.5%. The company is not currently anticipate fourth quarter year-on-year revenue growth due to the impact of the skincare business disposal, challenging 2019 comparatives together with increasing uncertainty linked to rising global COVID infection rates.Is New 90 Day High Low • Oct 07New 90-day low: €1.90The company is down 12% from its price of €2.15 on 09 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.94 per share.공시 • Oct 06+ 1 more updateMedline Industries, Inc. completed the acquisition of Aloe Vesta and SensiCare Skin Care Business of Convatec Group Plc (LSE:CTEC).Medline Industries, Inc. signed an agreement to acquire Aloe Vesta and SensiCare Skin Care Business of Convatec Group Plc (LSE:CTEC) for $29 million on July 30, 2020. The sale includes the Convatec business in both the U.S. and Canada and gives Medline global rights to market outside North America. The transaction is expected to close in the third quarter of 2020. Medline Industries, Inc. completed the acquisition of Aloe Vesta and SensiCare Skin Care Business of Convatec Group Plc (LSE:CTEC) on October 1, 2020. Carlos Hernandez of Seale & Associates, Inc. acted as financial advisor to Convatec Group.공시 • Sep 24Convatec Group Plc announced that it has received funding from The Carlyle Group Inc.Convatec Group Plc announced that it has received funding from new investor, Carlyle Mezzanine Partners II, L.P., a fund managed by The Carlyle Group Inc. in July 2008.Is New 90 Day High Low • Sep 22New 90-day low: €1.95The company is down 12% from its price of €2.23 on 24 June 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.77 per share.공시 • Sep 19+ 1 more updateConvatec Group Plc (LSE:CTEC) completed the acquisition of asset of Southlake Medical Supplies, Inc. for $12.3 million.Convatec Group Plc (LSE:CTEC) signed an agreement to acquire asset of Southlake Medical Supplies, Inc. on September 18, 2019. The consideration is payable in cash. For the year ended December 31, 2018 Southlake delivered revenues of approximately $5 million. The acquisition is subject to the usual formalities and is expected to close on September 30, 2019. Convatec Group Plc (LSE:CTEC) completed the acquisition of asset of Southlake Medical Supplies, Inc. for $12.3 million on October 1, 2019.이익 및 매출 성장 예측DB:2CV - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20282,9164264396081512/31/20272,7453623915471712/31/20262,5712772934891712/31/20252,439175285470N/A9/30/20252,397196312474N/A6/30/20252,356217337478N/A3/31/20252,322204306437N/A12/31/20242,289191275397N/A9/30/20242,245172266388N/A6/30/20242,200153257379N/A3/31/20242,171142248373N/A12/31/20232,142130238367N/A9/30/20232,113100166300N/A6/30/20232,0847093232N/A3/31/20232,07867115257N/A12/31/20222,07363138282N/A9/30/20222,07472155285N/A6/30/20222,07580173287N/A3/31/20222,05799192297N/A12/31/20212,038118212306N/A9/30/20212,016128247341N/A6/30/20211,994139282375N/A3/31/20211,944126298387N/A12/31/20201,894113313400N/A9/30/20201,87068305381N/A6/30/20201,84624296363N/A3/31/20201,83717318382N/A12/31/20191,82710340402N/A9/30/20191,81386N/A391N/A6/30/20191,800162N/A381N/A3/31/20191,816192N/A367N/A12/31/20181,832222N/A352N/A9/30/20181,843230N/A351N/A6/30/20181,855239N/A351N/A3/31/20181,810199N/A329N/A12/31/20171,765158N/A307N/A9/30/20171,72826N/A225N/A6/30/20171,691-106N/A143N/A3/31/20171,700-150N/A117N/A12/31/20161,688-203N/A75N/A9/30/20161,694-46N/A83N/A6/30/20161,677-15N/A128N/A3/31/20161,658-175N/A100N/A12/31/20151,650-93N/A100N/A9/30/20151,622-325N/A134N/A6/30/20151,662-315N/A165N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 2CV 의 연간 예상 수익 증가율(20%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: 2CV 의 연간 수익(20%)이 German 시장(17.3%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 2CV 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: 2CV 의 수익(연간 6.1%)이 German 시장(연간 6.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 2CV 의 수익(연간 6.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 2CV의 자본 수익률은 3년 후 24.4%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/28 09:29종가2026/05/27 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Convatec Group PLC는 25명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hassan Al-WakeelBarclaysSamuel EnglandBerenbergSusannah LudwigBernstein22명의 분석가 더 보기
공시 • Nov 13Convatec Group plc Maintains Revenue Guidance for the Year 2025ConvaTec Group PLC maintained revenue guidance for the year 2025. FY25 Group organic revenue growth excluding InnovaMatrix 6.0-6.5% (previously 5.5-7.0%). Medium-term targets: 5-7% organic revenue.
공시 • Jul 31+ 1 more updateConvaTec Group PLC Provides Revenue Guidance for the Year 2025ConvaTec Group PLC provided revenue guidance for the year 2025. Group organic revenue growth excluding InnovaMatrix of 5.5%-7.0% (unchanged) driven by broadening product portfolio and focused commercial execution. InnovaMatrix® revenue of at least $75 million (unchanged).
공시 • May 17ConvaTec Group PLC Provides Revenue Guidance for the Full Year 2024ConvaTec Group PLC provided revenue guidance for the full year 2024. Given the strong start so far this year, the company expects more balanced growth between first half and the second half of the year, and the company is on track to deliver its full year guidance of 5% to 7% organic revenue growth.
공시 • Nov 14ConvaTec Group PLC Revises Earnings Guidance for the Year 2023ConvaTec Group PLC revised earnings guidance for the year 2023. For the year, the company now expect organic revenue growth for 2023 to be between 6.75% and 7.5% (previously 6.0%-7.5%).
공시 • May 19ConvaTec Group PLC Provides Revenue Guidance for the Year 2023ConvaTec Group PLC provided revenue guidance for the year 2023. For the year, the company now expects organic revenue growth to be between 5.0% and 6.5% (previously 4.5%-6.0%).
공시 • Nov 10ConvaTec Group plc Provides Revenue Guidance for the Full Year of 2022ConvaTec Group Plc provided revenue guidance for the full year of 2022. Following sustained good sales growth, guidance for 2022 organic revenue growth has been increased to 5.4% to 5.8% (previously 4.0% to 5.5%.).
Board Change • May 20Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Group Financial Controller, CFO & Director Fiona Ryder was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • May 06Convatec Showcases and Launches Advanced Wound Care Products and TechnologiesConvatec, a medical products and technology company focused on chronic condition management, took to the stage to showcase the breadth, depth and momentum behind its Advanced Wound Care innovation pipeline at the European Wound Management Association (EWMA) 2026 conference in Bremen, Germany, from 6–8 May 2026. Convatec’s Advanced Wound Care innovation is supported by compelling new data from randomised controlled trials (RCTs) and real-world studies, with 13 abstracts accepted for publication and presentation at EWMA evaluating outcomes in hard-to-heal wounds across foam, multimodal, nitric oxide-generating dressings, antimicrobial technology and Wound Hygiene. Convatec has launched or secured approvals for five new wound care products since 2022, including: ConvaFoam™: Best-in-class multi-layer foam dressing designed to be repositionable on application to avoid wasted dressing changes. ConvaFoam™ is the only foam dressing that combines three technologies – Aquacel® Hydrofiber®, superabsorber fibers and ConvaTac™ silicone – to deliver superior exudate management with skin friendly adhesion for longer lasting wear time. ConvaNiox™: A solution, shaping a new category in the management of hard-to-heal wounds by combining an advanced dressing technology with a powerful antimicrobial and antibiofilm agent, nitric oxide. ConvaNiox™’s multimodal technology, MultiFusion™, supports the healing of 60% more diabetic foot ulcers (DFUs), with 3x faster wound area reduction compared to standard-of-care dressings. Aquacel™ ConvaFiber™: Next-generation, soft, sterile and conformable primary dressing with advanced Hydrofiber® technology resulting in 45% more absorbency (vs Aquacel® Extra™), designed to manage a broad range of acute and chronic wounds. ConvaMatrix™: Recently approved innovative, single use wound matrix - a unique porcine placental-derived technology designed to support the body's natural healing response in DFUs and venous leg ulcers (VLUs). It combines the structural benefits of the placenta with the reproducibility and safety profile of a medical device. ConvaVAC™: First and only Negative Pressure Wound Therapy (NPWT) system partnered with Aquacel® Hydrofiber® technology utilising a bacterial sequestration and autolytic debridement wound contact layer to control the bioburden whilst delivering NPWT to promote wound healing. This year’s EWMA programme also marks 30 years of Hydrofiber® technology, Convatec’s proprietary wound care platform that underpins the next generation of wound care innovation to help manage the burden of wound care. Almost 1,500,000,000 Aquacel® dressings have been sold worldwide leveraging the technology over the last three decades. As part of the scientific programme at EWMA 2026, Convatec will host a series of symposia to explore emerging evidence from across its Advanced Wound Care portfolio and discuss what it means for real-world clinical practice, including: 6 May 2026 from 16:00 – 17:00: Introducing ConvaNiox™: multimodal, nitric oxide-generating dressing. The session, chaired by Professor José Luis Lázaro-Martínez, University of Madrid, will explore emerging laboratory and clinical evidence, highlighting ConvaNiox™’s multimodal approach to support healing in diabetic foot ulcers. 7 May 2026 from 16:16 – 17:15: A year of healing with ConvaFoam™: Advancing wound care with a next-generation foam dressing. The session will focus on the published clinical data exploring ConvaFoam™’s mode of action in pressure injury prevention, including insights on complex cases from guest speaker Dr Przemyslaw Lipinski, ARGO Medical Centre. Title Lead presenter Session information (CEST) Aquacel® Ag+ Extra™ Enhanced silver dressing versus dialkylcarbamoyl chloride-coated dressing in venous leg ulcers: a blinded re-assessment of randomized controlled trial findings Rebecca Rodger Wednesday 6 May 17:35 - 17:43 Room 4B Enhanced silver dressing improves slough and debridement in venous leg ulcers: post hoc analysis of a randomised controlled trial Rebecca Rodger Thursday 07 May 13:33 – 13:37 E-Poster Screen 4 ConvaNiox™ Assessing the speed of antimicrobial activity of a nitric oxide-generating dressing against antibiotic-resistant wound pathogens Tilly Coleborn Wednesday 6 May 12:17 - 12:21 E-Poster Screen 2 Assessing the sustained antimicrobial activity of a nitric oxide-generating dressing using antibiotic-resistant wound pathogens in a repeated inoculation model Tilly Coleborn Wednesday 6 May 12:21 - 12:25 E-Poster Screen 2 A multimodal dressing NO-generating: An Option for Both Acute and Chronic Wounds Dr. Francesca Pasquali Wednesday 6 May 12:29 - 12:33 CEST E-Poster Screen 2 Effectiveness of a nitric oxide-generating dressing in patients with diabetic foot ulcers: preliminary data from a case series study Dr. Marco Meloni Thursday 7 May 13:20 - 13:25 E-Poster Screen 3 To assess real-world characteristics and short-term outcomes of diabetic foot ulcers (DFUs) managed with a multi-modal nitric oxide-generating medical device using a structured clinical follow-up case report form Natalia Maella-Rius Thursday 7 May 13:30 - 13:35 E-Poster Screen 3 ConvaFoam™ Performance and user satisfaction with a superabsorbent dressing: results from an international survey Janet MacKenzie Thursday 7 May 12:54 – 12:57 E-Poster Screen 2 Early outcomes of implementing a new multilayer foam dressing in an acute setting: Assessing clinical and financial impact through value-based procurement Rebecca Rodger Thursday 7 May 16:10 - 16:15 E-Poster Screen 4 ConvaMatrix™ The clinical performance of decellularized porcine placental extracellular matrix (PPECM) in hard-to-heal wounds at a single-center: a retrospective study Helen Hahn Wednesday 6 May 00:00 - 00:00 E-poster browsing stations for display Real-world use of porcine placental extracellular matrix (PPECM) in hard-to-heal wounds: retrospective, multicenter analysis Helen Hahn Wednesday 6 May 00:00 - 00:00 E-poster browsing stations for display Real world data Hospital-to-home transition and care coordination in wound management: cost-effectiveness evaluation in a Brazilian specialized service Michele Rocha Thursday 7 May 10:36 - 10:39 E-Poster Screen 4 Therapeutic success indicators in hard-to-heal wounds: effectiveness of a specialized ambulatory care model Michele Rocha Thursday 7 May 16:30 - 16:35 E-Poster Screen 4.
공시 • Apr 13Convatec Group Plc Announces Professor Constantin Coussios OBE Steps Down as Non-Executive Director, Effective April 30, 2026Convatec Group Plc announces that Professor Constantin Coussios OBE will be stepping down as a Non-Executive Director of Convatec Group Plc with effect from April 30, 2026 as he takes up his new appointment as Pro-Vice-Chancellor for Innovation at the University of Oxford. Since his appointment in September 2020, Professor Coussios has worked closely with the Board, senior management and Convatec's Chief Science, Innovation & Quality Officer Dr Divakar Ramakrishnan to transform and re-shape Convatec's research and development capabilities, accelerate new product development, and position the Company for sustained, innovation-led growth. Over the past six years, Convatec has completed several transformative strategic acquisitions, its internal new product development cycle time has been compressed by approximately 30%, and the vitality index has strengthened steadily from approximately 10% to approximately 30%, with 16 new product launches underway since 2022. The company confirms that the resolution to re-elect Professor Coussios as a Non-Executive Director of the company (resolution number 9) is now withdrawn.
공시 • Mar 18Convatec Group PLC to Report First Half, 2026 Results on Aug 04, 2026Convatec Group PLC announced that they will report first half, 2026 results on Aug 04, 2026
공시 • Mar 17Convatec and Eakin Healthcare Introduce Co-Branded Eakin Freeseal Ostomy Seal in North America Expanding the Esenta Family of AccessoriesConvatec, a medical products and technologies company focused on solutions for the management of chronic conditions, and Eakin Healthcare, a provider of ostomy solutions, announced the launch of eakin freeseal, the thinnest ostomy seal used to help prevent leaks and protect the skin around a stoma. This new co-branded seal is part of the ESENTA family of accessories, available in the United States. Ostomy seals are designed to create a protective layer around the stoma to prevent leakage. Recurrent leakage can lead to skin breakdown and irritation, leading to longer term issues, both physically and emotionally for patients. With approximately 1 million people living with a stoma in the United States, about 90% experience leakage at some point in their journey. The use of ostomy seals can reduce or eliminate leakage, leading to a better quality of life for those living with an ostomy. The eakin freeseal range includes two product lines, eakin freeseal air, and eakin freeseal versa, providing healthcare professionals with versatile options that combine discretion, comfort and high performance. While Convatec currently addresses the patient's needs with the eakin Cohesive seal, eakin freeseal provides healthcare professionals with a wider range of options to meet their clinical needs. The thinner offering, eakin freeseal air has a depth starting at 1.8mm, making it the thinnest seal on the market and is designed to be paired with convex pouches. Eakin freeseal versa is slightly thicker and designed to absorb fluid at the best rate in the market without breaking down, leading to easier removal for the end user. The thinness of this new ostomy seal, together with its composition and design, allows it to absorb up to four times its weight in fluid without breaking down underneath the skin barrier. This high performance, combined with eakin seals’ moldability, makes eakin freeseal a relatable solution to any person living with a stoma immediately post-surgery. Ostomy seals and barriers designed to prevent leakage and skin irritation is one of the largest product categories in the United States and continues to grow at a consistent rate. This co-branded product reflects Convatec and Eakin Healthcare’s ongoing commitment to patients and healthcare professionals to provide choice – working together to provide a better ostomy experience so patients can live the life they want. Integrating eakin seals into the ESENTA range reinforces the importance of using a reliable ostomy seal as part of the customers skincare routine.
공시 • Feb 25Convatec Group PLC, Annual General Meeting, May 21, 2026Convatec Group PLC, Annual General Meeting, May 21, 2026.
공시 • Feb 24Convatec Group PLC Recommends Final Dividend for the Year 2025, Payable on 28 May 2026Convatec Group PLC has recommended a final 2025 dividend of 5.367 cents per share, which would bring the full-year dividend to 7.244 cents per share (2024: 6.416 cents per share), an increase of 13% and a pay-out ratio when compared to adjusted net profit of 40% (2024: 42%). Ex-dividend is on 16 April 2026 with Record date on 17 April 2026. Payment date on 28 May 2026.
공시 • Nov 13Convatec Group plc Maintains Revenue Guidance for the Year 2025ConvaTec Group PLC maintained revenue guidance for the year 2025. FY25 Group organic revenue growth excluding InnovaMatrix 6.0-6.5% (previously 5.5-7.0%). Medium-term targets: 5-7% organic revenue.
공시 • Nov 08+ 2 more updatesConvaTec Group PLC Appoints Jonny Mason as Chief Executive Officer, Effective November 6, 2025ConvaTec Group PLC Board of Directors announced the appointment of Jonny Mason as Chief Executive Officer, effective November 6, 2025.Jonny Mason joined Convatec on 31 January 2022 as Chief Financial Officer and became a Director of the Company from 12 March 2022. He was appointed Interim CEO on 4 August 2025.
공시 • Oct 28Convatec Group plc Announces Demise of Karim Bitar, Chief Executive OfficerConvaTec Group PLC announced that its Karim Bitar, who has been on medical leave of absence since 4 August 2025, has passed away. As previously announced, interim leadership arrangements remain in place and a further announcement will be made in due course.
공시 • Aug 04+ 1 more updateConvaTec Group PLC Announces Change of Chief Executive OfficerConvatec announced that Chief Executive Officer Karim Bitar will be taking a medical leave of absence from the Company. During this period of absence, Jonny Mason, currently Chief Financial Officer, will become Interim Chief Executive Officer. Jonny and Fiona joined the Company in January 2022.
공시 • Jul 31+ 1 more updateConvaTec Group PLC Provides Revenue Guidance for the Year 2025ConvaTec Group PLC provided revenue guidance for the year 2025. Group organic revenue growth excluding InnovaMatrix of 5.5%-7.0% (unchanged) driven by broadening product portfolio and focused commercial execution. InnovaMatrix® revenue of at least $75 million (unchanged).
공시 • Jul 29ConvaTec Group PLC to Report Fiscal Year 2025 Results on Feb 25, 2026ConvaTec Group PLC announced that they will report fiscal year 2025 results on Feb 25, 2026
공시 • Feb 27ConvaTec Group PLC, Annual General Meeting, May 22, 2025ConvaTec Group PLC, Annual General Meeting, May 22, 2025.
공시 • Feb 26+ 1 more updateConvaTec Group PLC Recommends Final Dividend for the Year 2024, Payable on 29 May 2025The Board of ConvaTec Group PLC recommends a final dividend of 4.594 cents, resulting in a full year dividend of 6.416 cents, an increase of 3%. The final dividend proposed for 2024 is to be distributed on 29 May 2025 to shareholders on the register at the close of business on 22 April 2025 and is subject to shareholder approval at the Annual General Meeting on 22 May 2025. Ex-dividend 17 April 2025.
공시 • Dec 17ConvaTec Group PLC to Report Fiscal Year 2024 Results on Feb 26, 2025ConvaTec Group PLC announced that they will report fiscal year 2024 results on Feb 26, 2025
New Risk • Nov 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (75% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.1% average weekly change).
Valuation Update With 7 Day Price Move • Nov 13Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €3.04, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €4.83 per share.
Upcoming Dividend • Aug 16Upcoming dividend of UK£0.014 per shareEligible shareholders must have bought the stock before 22 August 2024. Payment date: 04 October 2024. Payout ratio is on the higher end at 84%, however this is supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (1.9%).
Declared Dividend • Aug 02First half dividend of UK£0.014 announcedShareholders will receive a dividend of UK£0.014. Ex-date: 22nd August 2024 Payment date: 4th October 2024 Dividend yield will be 2.0%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (84% earnings payout ratio) and cash flows (50% cash payout ratio). The dividend has increased by an average of 12% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 76% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Aug 01First half 2024 earnings released: EPS: US$0.038 (vs US$0.027 in 1H 2023)First half 2024 results: EPS: US$0.038 (up from US$0.027 in 1H 2023). Revenue: US$1.11b (up 5.5% from 1H 2023). Net income: US$78.6m (up 41% from 1H 2023). Profit margin: 7.1% (up from 5.3% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 2% per year.
공시 • May 17ConvaTec Group PLC Provides Revenue Guidance for the Full Year 2024ConvaTec Group PLC provided revenue guidance for the full year 2024. Given the strong start so far this year, the company expects more balanced growth between first half and the second half of the year, and the company is on track to deliver its full year guidance of 5% to 7% organic revenue growth.
Upcoming Dividend • Apr 18Upcoming dividend of UK£0.035 per shareEligible shareholders must have bought the stock before 25 April 2024. Payment date: 23 May 2024. Payout ratio is on the higher end at 97%, however this is supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (1.8%).
공시 • Apr 16Convatec Launches New Esteem Body with Leak DefenseConvatec announced that it has launched Esteem Body™ with Leak Defense™ in the United States. The use of soft convexity ostomy barriers, starting post-surgery, is a growing practice fueled in part by global obesity, which has nearly tripled since 1975. The trend has driven abdominal topography changes and related challenges for ostomy care management, such as skin folds and complicated abdominal contours. Convatec's new offering to address this growing patient need is a comprehensive, one-piece, soft convexity ostomy system portfolio designed to fit a full range of body types and stoma shapes. The portfolio includes drainable, closed-end, and urostomy pouching solutions. There are five principal characteristics of convexity design, with two of these – 'tension location' and 'convex depth' - serving as significant drivers for achieving clinical goals of stoma protrusion and/or skin flattening. Convatec's Esteem Body™ offers eight different combinations of these key characteristics, with four 'tension locations' (split centrally and peripherally) across two different 'convex depths'. This range gives greater choice and provides the healthcare provider and ostomate the ability to achieve the best possible fit, given that each person living with an ostomy is unique. Leak Defense™ refers to the exclusive combination of Convatec's gold-standard adhesives (Durahesive® and Modified Stomahesive®) coupled with the comprehensive, soft convexity range, which together are designed to adapt to the body for a secure seal that can help prevent leaks and achieve a predictable wear time. The product also offers Convatec's new 'body' pouch, which comes in a patented '8-shape' that has been designed to sag less as it fills. The soft yet water-repellent 'flocking' material, that covers both sides of the pouch, is a warm gray color that hides content, even when wet, and is also discreet, even when worn under white clothing. The flocking was selected to optimise the functionality and discretion of Convatec's new, modern-looking and feeling pouch design. Convatec has recently published Finite Element Analysis (FEA) simulations that help visualize how both magnitude and location, of the tension applied to the ostomy and its surrounding multi-layer tissue, change in accordance with the product selected. It was clear how both tension location and convex depth are key contributors, working together with all convexity characteristics to achieve clinical stoma management goals. The FEA work is the foundation for the scientific and translational work Convatec is doing in ostomy care, and upon which research will be expanded to support clinicians and ostomates.
공시 • Mar 08+ 1 more updateConvaTec Group plc Recommends Final Dividend, Payable on 23 May 2024ConvaTec Group PLC recommended final dividend of 4.460 cents resulting in full year dividend of 6.229 cents, an increase of 3%. The dividend will be payable on 23 May 2024 with Ex Dividend of 25 April 2024 and Record Date of 26 April 2024. The dividend is subject to shareholder approval at the Annual General Meeting on 16 May 2024.
Reported Earnings • Mar 07Full year 2023 earnings released: EPS: US$0.064 (vs US$0.031 in FY 2022)Full year 2023 results: EPS: US$0.064 (up from US$0.031 in FY 2022). Revenue: US$2.14b (up 3.4% from FY 2022). Net income: US$130.3m (up 107% from FY 2022). Profit margin: 6.1% (up from 3.0% in FY 2022). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
공시 • Mar 06ConvaTec Group PLC, Annual General Meeting, May 16, 2024ConvaTec Group PLC, Annual General Meeting, May 16, 2024. Agenda: To consider Final Dividend.
공시 • Feb 16ConvaTec Group PLC to Report First Half, 2024 Results on Jul 30, 2024ConvaTec Group PLC announced that they will report first half, 2024 results on Jul 30, 2024
Buy Or Sell Opportunity • Feb 15Now 20% undervaluedOver the last 90 days, the stock has risen 7.7% to €2.80. The fair value is estimated to be €3.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has declined by 6.6%. For the next 3 years, revenue is forecast to grow by 5.3% per annum. Earnings are also forecast to grow by 24% per annum over the same time period.
Buying Opportunity • Jan 05Now 21% undervaluedOver the last 90 days, the stock is up 10%. The fair value is estimated to be €3.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has declined by 6.6%. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings is also forecast to grow by 27% per annum over the same time period.
공시 • Nov 14ConvaTec Group PLC Revises Earnings Guidance for the Year 2023ConvaTec Group PLC revised earnings guidance for the year 2023. For the year, the company now expect organic revenue growth for 2023 to be between 6.75% and 7.5% (previously 6.0%-7.5%).
공시 • Sep 14ConvaTec Group PLC to Report Fiscal Year 2023 Results on Mar 06, 2024ConvaTec Group PLC announced that they will report fiscal year 2023 results on Mar 06, 2024
공시 • Sep 08+ 1 more updateAn unknown buyer acquired an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S.An unknown buyer acquired an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S on September 8, 2023. Sten Scheibye will be stepping down from the Board. An unknown buyer completed the acquisition of an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S on September 8, 2023.
Upcoming Dividend • Aug 10Upcoming dividend of UK£0.014 per share at 2.1% yieldEligible shareholders must have bought the stock before 17 August 2023. Payment date: 28 September 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.9%).
공시 • Aug 04+ 1 more updateConvaTec Group plc Declares Interim Dividend for the Six Months Ended June 30, 2023ConvaTec Group PLC is declaring a 3% increase in the interim dividend to 1.769 cents per share (H1 2022: 1.717) reflecting continued confidence in the future performance of the Group and cash generation.
New Risk • Aug 03New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 18% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Payout ratio: 176% Cash payout ratio: 111% Minor Risk Large one-off items impacting financial results.
Reported Earnings • Aug 03First half 2023 earnings released: EPS: US$0.027 (vs US$0.024 in 1H 2022)First half 2023 results: EPS: US$0.027 (up from US$0.024 in 1H 2022). Revenue: US$1.06b (up 1.1% from 1H 2022). Net income: US$55.7m (up 15% from 1H 2022). Profit margin: 5.3% (up from 4.6% in 1H 2022). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Buying Opportunity • Jul 24Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €3.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 4.4% per annum. Earnings is also forecast to grow by 26% per annum over the same time period.
Buying Opportunity • Jul 06Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 7.1%. The fair value is estimated to be €2.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 4.4% per annum. Earnings is also forecast to grow by 25% per annum over the same time period.
공시 • May 19ConvaTec Group PLC Provides Revenue Guidance for the Year 2023ConvaTec Group PLC provided revenue guidance for the year 2023. For the year, the company now expects organic revenue growth to be between 5.0% and 6.5% (previously 4.5%-6.0%).
Upcoming Dividend • Mar 30Upcoming dividend of UK£0.037 per share at 2.2% yieldEligible shareholders must have bought the stock before 06 April 2023. Payment date: 25 May 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.2%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).
Reported Earnings • Mar 10Full year 2022 earnings released: EPS: US$0.031 (vs US$0.059 in FY 2021)Full year 2022 results: EPS: US$0.031 (down from US$0.059 in FY 2021). Revenue: US$2.07b (up 1.7% from FY 2021). Net income: US$62.9m (down 47% from FY 2021). Profit margin: 3.0% (down from 5.8% in FY 2021). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Dec 24Group CFO & Director recently bought €73k worth of stockOn the 19th of December, Jonathan Mason bought around 28k shares on-market at roughly €2.60 per share. This transaction increased Jonathan's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jonathan has been a buyer over the last 12 months, purchasing a net total of €131k worth in shares.
공시 • Dec 14ConvaTec Group Plc to Report Fiscal Year 2022 Results on Mar 09, 2023ConvaTec Group Plc announced that they will report fiscal year 2022 results on Mar 09, 2023
Board Change • Nov 17High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Group CFO & Director Jonny Mason was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Nov 10ConvaTec Group plc Provides Revenue Guidance for the Full Year of 2022ConvaTec Group Plc provided revenue guidance for the full year of 2022. Following sustained good sales growth, guidance for 2022 organic revenue growth has been increased to 5.4% to 5.8% (previously 4.0% to 5.5%.).
Buying Opportunity • Nov 03Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €3.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 26% per annum over the same time period.
공시 • Sep 19+ 1 more updateConvaTec Group Plc(LSE:CTEC) dropped from FTSE 250 IndexConvaTec Group Plc(LSE:CTEC) dropped from FTSE 250 Index
Buying Opportunity • Sep 03Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 4.7%. The fair value is estimated to be €3.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 3.6% per annum. Earnings is also forecast to grow by 31% per annum over the same time period.
Upcoming Dividend • Aug 18Upcoming dividend of UK£0.014 per shareEligible shareholders must have bought the stock before 25 August 2022. Payment date: 06 October 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (1.1%).
Reported Earnings • Aug 05First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down US$85.8m from profit in 1H 2021). Profit margin: (down from 8.5% in 1H 2021). Over the next year, revenue is forecast to grow 1.2%, compared to a 7.2% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 15% per year.
공시 • Aug 04+ 1 more updateConvatec Group plc Declares an Unchanged Interim Dividend for First Half of 2022ConvaTec Group Plc announced that the Board is declaring an unchanged interim dividend of 1.717 cents per share (H1 2021: 1.717) reflecting continued confidence in the future performance of the Group and cash generation.
공시 • May 12ConvaTec Group Plc Provides Earnings Guidance for the Full Year 2022ConvaTec Group Plc provides earnings guidance for the full year 2022. For the period, the company expects organic revenue growth of between 4.0% and 5.5% and a constant currency EBIT margin of at least 18%.
Board Change • Apr 27High number of new directorsThere are 8 new directors who have joined the board in the last 3 years. Group CFO & Director Jonny Mason was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Mar 24Upcoming dividend of UK£0.032 per shareEligible shareholders must have bought the stock before 31 March 2022. Payment date: 19 May 2022. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.2%. Lower than top quartile of German dividend payers (3.6%). Higher than average of industry peers (1.1%).
공시 • Mar 10Convatec Group plc Proposes Final Dividend for Year 2021, Payable on May 19, 2022ConvaTec Group Plc proposed the final dividend of 4.154 cents for year 2021, to be distributed on 19 May 2022 to shareholders registered at the close of business on 1 April 2022, is based upon the issued and fully paid share capital as at 31 December 2021 and is subject to shareholder approval at the Annual General Meeting on 12 May 2022. Ex-dividend date is March 31, 2022.
Reported Earnings • Mar 09Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$0.059 (up from US$0.056 in FY 2020). Revenue: US$2.04b (up 7.6% from FY 2020). Net income: US$117.6m (up 4.5% from FY 2020). Profit margin: 5.8% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 3.5%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 09Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: US$0.059 (up from US$0.056 in FY 2020). Revenue: US$2.04b (up 7.6% from FY 2020). Net income: US$117.6m (up 4.5% from FY 2020). Profit margin: 5.8% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 3.5%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
공시 • Mar 01Convatec Group plc Announces Board ChangesConvaTec Group Plc announced the appointment of Sharon O'Keefe as a Non-Executive Director of the Company with effect from March 1, 2022. Sharon will join ConvaTec's Remuneration and Nomination committees on the same date. The Company also announces that Rick Anderson, Non-Executive Director, is stepping down from the Board with effect from 3 March 2022. Rick has made a significant and valuable contribution to ConvaTec since 2016 for which the Board is immensely grateful. Rick is also Chairman and MD of Revival Healthcare Capital, a role which has recently expanded, and this has led to his reluctant decision to step down from the Board of ConvaTec. Sharon has over 40 years of healthcare and executive experience, with particular focus on quality, efficiency and innovation to create high performance healthcare organisations.
공시 • Jan 30ConvaTec Group Plc (LSE:CTEC) agreed to acquire Triad Life Sciences, Inc. for $450 million.ConvaTec Group Plc (LSE:CTEC) agreed to acquire Triad Life Sciences, Inc. for $450 million on January 28, 2022. The initial consideration is $125 million with two potential additional payments of $25 million each relating to short-term milestones. There are also two earnout payments conditional on performance during year 1 and year 2 post completion, with the maximum earnout of $275 million based on stretching financial performance over the period. The consideration will be satisfied from existing cash balances and debt facilities. The gross assets of Triad Life Sciences were $23 million at 30 June 2021. Russell Olsen, the Founder and Chief Executive Officer of Triad Life Sciences, will be the General Manager of the business, reporting directly into David Shepherd, President and Chief Operating Officer of Global Advanced Wound Care. The transaction, which is subject to regulatory approvals and other customary conditions, is expected to close during Q1 2022. The transaction is expected to be immediately accretive to sales growth and the return on invested capital is expected to exceed the Group's cost of capital in year three.
공시 • Jan 28ConvaTec Group Plc Appoints Constantin Coussios as Member of Remuneration Committee and Nomination CommitteeConvaTec Group Plc announced that Professor Constantin Coussios, a Non-Executive Director of the Company, has been appointed as a member of the Company's Remuneration Committee and Nomination Committee.
Upcoming Dividend • Aug 26Upcoming dividend of UK£0.012 per shareEligible shareholders must have bought the stock before 02 September 2021. Payment date: 14 October 2021. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (3.1%). Higher than average of industry peers (0.8%).
Reported Earnings • Aug 01First half 2021 earnings released: EPS US$0.043 (vs US$0.03 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$1.01b (up 11% from 1H 2020). Net income: US$85.8m (up 45% from 1H 2020). Profit margin: 8.5% (up from 6.5% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Executive Departure • May 04Company Secretary has left the companyOn the 30th of April, Clare Bates' tenure in the role of Company Secretary ended. We don't have any record of a personal shareholding under Clare's name. A total of 2 executives have left over the last 12 months.
공시 • Apr 29ConvaTec Group plc Provides Financial Guidance for the Year 2021ConvaTec Group Plc provided financial guidance for the year 2021. Given the continuing macro uncertainties at this early point in the year and relatively tougher comparatives in the second half, guidance remains unchanged with organic1 revenue growth of 3% to 4.5%.
Upcoming Dividend • Mar 26Upcoming dividend of UK£0.028 per shareEligible shareholders must have bought the stock before 01 April 2021. Payment date: 13 May 2021. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.3%). Higher than average of industry peers (1.1%).
Reported Earnings • Mar 24Full year 2020 earnings released: EPS US$0.056 (vs US$0.005 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$1.89b (up 3.7% from FY 2019). Net income: US$112.5m (up US$102.7m from FY 2019). Profit margin: 5.9% (up from 0.5% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 06Full year 2020 earnings released: EPS US$0.056 (vs US$0.005 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$1.89b (up 3.7% from FY 2019). Net income: US$112.5m (up US$102.7m from FY 2019). Profit margin: 5.9% (up from 0.5% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Analyst Estimate Surprise Post Earnings • Mar 06Revenue beats expectationsRevenue exceeded analyst estimates by 0.4%. Over the next year, revenue is forecast to grow 5.6%, compared to a 13% growth forecast for the Medical Equipment industry in Germany.
공시 • Mar 05Convatec Group Plc, Annual General Meeting, May 07, 2021Convatec Group Plc, Annual General Meeting, May 07, 2021.
공시 • Feb 23Convatec Group Plc to Report Fiscal Year 2020 Results on Mar 05, 2021Convatec Group Plc announced that they will report fiscal year 2020 results on Mar 05, 2021
Is New 90 Day High Low • Feb 23New 90-day low: €2.16The company is down 4.0% from its price of €2.26 on 24 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.39 per share.
Is New 90 Day High Low • Feb 04New 90-day high: €2.30The company is up 8.0% from its price of €2.13 on 06 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.40 per share.
Is New 90 Day High Low • Nov 11New 90-day high: €2.25The company is up 3.0% from its price of €2.18 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.91 per share.
공시 • Oct 29Convatec Group plc Revises Revenue Guidance for the Year 2020Convatec Group Plc revised full year guidance and now expect to be towards the higher end of constant currency revenue growth range of 2%-3.5%. The company is not currently anticipate fourth quarter year-on-year revenue growth due to the impact of the skincare business disposal, challenging 2019 comparatives together with increasing uncertainty linked to rising global COVID infection rates.
Is New 90 Day High Low • Oct 07New 90-day low: €1.90The company is down 12% from its price of €2.15 on 09 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.94 per share.
공시 • Oct 06+ 1 more updateMedline Industries, Inc. completed the acquisition of Aloe Vesta and SensiCare Skin Care Business of Convatec Group Plc (LSE:CTEC).Medline Industries, Inc. signed an agreement to acquire Aloe Vesta and SensiCare Skin Care Business of Convatec Group Plc (LSE:CTEC) for $29 million on July 30, 2020. The sale includes the Convatec business in both the U.S. and Canada and gives Medline global rights to market outside North America. The transaction is expected to close in the third quarter of 2020. Medline Industries, Inc. completed the acquisition of Aloe Vesta and SensiCare Skin Care Business of Convatec Group Plc (LSE:CTEC) on October 1, 2020. Carlos Hernandez of Seale & Associates, Inc. acted as financial advisor to Convatec Group.
공시 • Sep 24Convatec Group Plc announced that it has received funding from The Carlyle Group Inc.Convatec Group Plc announced that it has received funding from new investor, Carlyle Mezzanine Partners II, L.P., a fund managed by The Carlyle Group Inc. in July 2008.
Is New 90 Day High Low • Sep 22New 90-day low: €1.95The company is down 12% from its price of €2.23 on 24 June 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.77 per share.
공시 • Sep 19+ 1 more updateConvatec Group Plc (LSE:CTEC) completed the acquisition of asset of Southlake Medical Supplies, Inc. for $12.3 million.Convatec Group Plc (LSE:CTEC) signed an agreement to acquire asset of Southlake Medical Supplies, Inc. on September 18, 2019. The consideration is payable in cash. For the year ended December 31, 2018 Southlake delivered revenues of approximately $5 million. The acquisition is subject to the usual formalities and is expected to close on September 30, 2019. Convatec Group Plc (LSE:CTEC) completed the acquisition of asset of Southlake Medical Supplies, Inc. for $12.3 million on October 1, 2019.